Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
2.240
+0.130 (6.16%)
At close: Jul 14, 2025, 4:00 PM
2.190
-0.050 (-2.23%)
After-hours: Jul 14, 2025, 4:15 PM EDT
Celularity Revenue
In the year 2024, Celularity had annual revenue of $54.22M with 138.11% growth. Celularity had revenue of $18.13M in the quarter ending December 31, 2024, with 49.70% growth.
Revenue (ttm)
$54.22M
Revenue Growth
+138.11%
P/S Ratio
0.85
Revenue / Employee
$440,813
Employees
123
Market Cap
53.65M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CELU News
- 5 days ago - Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law - GlobeNewsWire
- 13 days ago - Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies - GlobeNewsWire
- 4 weeks ago - Celularity Announces Chief Financial Officer Transition - GlobeNewsWire
- 6 weeks ago - Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology - GlobeNewsWire
- 6 weeks ago - Celularity Receives Nasdaq Notice Regarding Form 10-Q - GlobeNewsWire
- 2 months ago - Celularity Announces Full Year 2024 Operating and Financial Results - GlobeNewsWire
- 2 months ago - Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - GlobeNewsWire
- 3 months ago - Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - GlobeNewsWire